Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?

Expert Rev Anticancer Ther. 2020 Apr;20(4):229-231. doi: 10.1080/14737140.2020.1744437. Epub 2020 Mar 24.

Authors

Takuro Goto^{1

2}, Hiroshi Miyamoto^{1

2

3}

Affiliations

¹ Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
² James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
³ Department of Urology, University of Rochester Medical Center, Rochester, NY, USA.

PMID: 32208041
DOI: 10.1080/14737140.2020.1744437

No abstract available

Keywords: Bladder cancer; chemotherapy; cystectomy; immunotherapy; prognosis; targeted therapy.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Transitional Cell / pathology
Carcinoma, Transitional Cell / therapy*
Combined Modality Therapy
Humans
Neoplasm Invasiveness
Prognosis
Survival Rate
Urinary Bladder Neoplasms / pathology
Urinary Bladder Neoplasms / therapy*